☆ 4.3 Review

Understanding resistance to immune checkpoint inhibitors in advanced breast cancer

EXPERT REVIEW OF ANTICANCER THERAPY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Pharmacology & Pharmacy

Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development

Paolo Tarantino et al.

Summary: The article discusses the immune landscape of TNBC and the rationale of NGIO in early development, highlighting challenges and opportunities. Multiple immunotherapeutic strategies beyond PD-(L)1 blockade have shown safety and early signs of antitumor activity. Refining patient selection based on emerging immune biomarkers and adapting immunotherapeutic strategies based on patient and tumor characteristics will be crucial for optimal harnessing the potential of NGIO.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)

添加到收藏夹

Review Oncology

Treatment landscape of triple-negative breast cancer - expanded options, evolving needs

Giampaolo Bianchini et al.

Summary: Recent advances in omics technologies have improved our understanding of the heterogeneity and microenvironment of triple-negative breast cancers (TNBCs), supporting a view of this breast cancer subtype as an ecosystem that encompasses both intrinsic and extrinsic features of cancer cells. The authors of this Review describe the current and upcoming therapeutic landscape of TNBC and discuss how an integrated view of the TNBC ecosystem can provide improved opportunities for tailoring treatment.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study

Barbara A. Conley et al.

Summary: Tumor molecular profiling from exceptional responders to systemic therapy can provide insights into cancer biology. This pilot study evaluated the feasibility of identifying these responders retrospectively and analyzing their pre-treatment tumor tissues with molecular tools. Results suggest that standard and investigational treatments can lead to exceptional responses, with potential actionable targets identified in molecular analyses.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial

Thomas Bachelot et al.

Summary: The study found that single-agent antibodies against PD-L1 as maintenance therapy did not significantly benefit the overall population with metastatic breast cancer, but showed improved overall survival in patients with triple-negative breast cancer. Durvalumab may have better sensitivity in patients with CD274 amplification. Analysis of lymphocyte infiltration and homologous recombination deficiency did not predict sensitivity to durvalumab, warranting further research. Maintenance chemotherapy was more effective than durvalumab in patients with hormone receptor-positive and Her2-negative disease.

NATURE MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

Erez N. Baruch et al.

Summary: This study conducted a phase 1 clinical trial and found that FMT treatment in patients with anti-PD-1-refractory metastatic melanoma, along with reinduction of anti-PD-1 immunotherapy, resulted in clinical responses in some patients. This suggests that modulating the gut microbiota could be a promising approach in cancer treatment.

SCIENCE (2021)

添加到收藏夹

Article Oncology

Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer

Abirami Sivapiragasam et al.

Summary: In this study, a large dataset of female metastatic breast cancers was analyzed using comprehensive genomic profiling to identify potential biomarkers associated with immunotherapy responsiveness. The study found various markers such as CD274 amplification, TMB, and MSI that may indicate response to immune checkpoint inhibitors in MBC. Furthermore, CGP shows promise in identifying genomic alterations linked to response and resistance to ICPI in MBC.

CANCER MEDICINE (2021)

添加到收藏夹

Review Oncology

The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality

Paolo Tarantino et al.

Summary: Precision medicine is changing oncology through the identification of biomarkers predictive of treatment response in cancer patients. Several biomarkers, including NTRK fusions, microsatellite instability, and high tumor mutational burden, have been approved regardless of tumor histology, indicating a histology-agnostic approach. However, histology-agnosticism is seen as a spectrum of actionability rather than a binary quality according to available evidence.

CANCER TREATMENT REVIEWS (2021)

添加到收藏夹

Review Oncology

Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials

Paolo Tarantino et al.

Summary: The addition of PD1/PD-L1 blockade to neoadjuvant chemo-immunotherapy significantly improves pCR rates in TNBC patients, particularly in the PD-Ll positive subgroup and high-risk subgroups, without increasing toxicity.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)

添加到收藏夹

Review Oncology

Immunotherapy as a partner for HER2-directed therapies

Guy T. Clifton et al.

Summary: HER2-targeted therapies can modulate the tumor microenvironment and the immune response in cancer. Combining these therapies with immunomodulatory drugs may have additive effects, but further studies are needed to confirm the benefits of these combinations. Initial trials with immune checkpoint inhibitors or cancer vaccines in combination with HER2-targeted therapies have shown mixed results, warranting additional research.

EXPERT REVIEW OF ANTICANCER THERAPY (2021)

添加到收藏夹

Article Oncology

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

Leisha A. Emens et al.

Summary: Understanding the impact of tumor immune microenvironment and BRCA1/2-related DNA repair deficiencies on the clinical activity of immune checkpoint inhibitors in metastatic triple-negative breast cancer may help optimize patient and treatment selection. The study found that PD-L1 expression and CD8-positive cells had an influence on the efficacy of immunotherapy.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

添加到收藏夹

Review Oncology

The Global Landscape of Treatment Standards for Breast Cancer

Dario Trapani et al.

Summary: Breast cancer treatment guidelines mainly come from English-speaking European and American regions, with half of the guidelines failing to achieve gender balance in authorship. Resource-stratified approaches are adopted in some resource-constrained settings, but national guidelines may not adequately consider local health-system capacity.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

添加到收藏夹

Article Oncology

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

Eric P. Winer et al.

Summary: Pembrolizumab did not significantly improve overall survival in patients with previously treated metastatic triple-negative breast cancer versus chemotherapy, indicating potential for further research in specific patient subpopulations and combination therapy for this disease.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

T. K. Choueiri et al.

Summary: The study demonstrates that nivolumab plus cabozantinib has significant advantages over sunitinib in the treatment of previously untreated advanced renal-cell carcinoma, including progression-free survival, overall survival, and likelihood of response.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article

Tumor mutational burden as a predictor of immunotherapy response in breast cancer

Tess A. O’Meara et al.

Oncotarget (2021)

添加到收藏夹

Review Microbiology

Human Microbiota and Breast Cancer-Is There Any Relevant Link?-A Literature Review and New Horizons Toward Personalised Medicine

Diogo Alpuim Costa et al.

Summary: Breast cancer is the most common malignancy in women from high-income countries, with gut microbiota dysbiosis potentially influencing its development and prognosis. Changes in gut microbiota composition may increase the risk of breast cancer and impact patient prognosis. Breast microbiota shows different signatures in tumour tissue and healthy tissue, suggesting a potential role in breast tumour carcinogenesis.

FRONTIERS IN MICROBIOLOGY (2021)

添加到收藏夹

Article Oncology

Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors

Giuseppe Curigliano et al.

Summary: The study aimed to evaluate the safety and efficacy of Sabatolimab and spartalizumab in patients with advanced solid tumors. The results showed that the combination of Sabatolimab plus spartalizumab was well tolerated and showed signs of antitumor activity, with the recommended dose for Sabatolimab being 800 mg Q4W, with or without 400 mg spartalizumab Q4W.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

Sara M. Tolaney et al.

Summary: The study investigated the efficacy and safety of combination therapy with eribulin and pembrolizumab in mTNBC, showing promising antitumor activity in this population. Efficacy outcomes appeared to be influenced by the line of therapy and PD-L1 status.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Pembrolizumab plus eribulin in hormone receptore-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase II trial

Jose M. Perez-Garcia et al.

Summary: This study demonstrated that the combination of chemotherapy and pembrolizumab in HR+, HER2-negative breast cancer patients can provide clinical benefit and has good safety and tolerability.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology

Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Ajjai S. Alva et al.

Summary: The TAPUR Study aims to identify antitumor activity of targeted agents in advanced cancer patients with specific genomic alterations. Results in a cohort of metastatic breast cancer patients treated with pembrolizumab show significant disease control and objective response rates, supporting the approval of pembrolizumab for certain solid tumors with high tumor mutational burden.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

Martin Reck et al.

Summary: This study reports the first 5-year follow-up of a first-line immunotherapy trial for NSCLC, demonstrating that pembrolizumab provides a durable, clinically meaningful long-term overall survival benefit in first-line treatment of metastatic NSCLC with a PD-L1 tumor proportion score of at least 50%.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Genetics & Heredity

Human breast microbiome correlates with prognostic features and immunological signatures in breast cancer

Alice Tzeng et al.

Summary: This study identified microbial profiles associated with prognostic clinicopathologic features in breast cancer through comparing healthy versus cancer-associated breast microbiomes. Additionally, it demonstrated evidence of local microbial-immune interplay in breast cancer, suggesting potential for prevention, diagnosis, and treatment.

GENOME MEDICINE (2021)

添加到收藏夹

Review Immunology

The Immunology of Hormone Receptor Positive Breast Cancer

Jonathan Goldberg et al.

Summary: ICB has revolutionized cancer treatment, but has limited efficacy in HR+ breast cancer due to a TME devoid of TILs. TNBC shows clinical responses to ICB due to TIL infiltration, while HR+ breast tumors establish an immune suppressive TME.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Oncology

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

D. Miles et al.

Summary: Combining atezolizumab with paclitaxel did not improve PFS or OS in PD-L1-positive aTNBC patients, although it showed some advantage in unconfirmed best overall response rate and duration of response.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Editorial Material Oncology

VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab plus pertuzumab plus trastuzumab plus chemotherapy (neoadj A plus PH plus CT) in high-risk, HER2-positive early breast cancer (EBC)

J. Huober et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab D chemotherapy vs. placebo D chemotherapy, followed by adjuvant pembrolizumab vs. placebo for earlystage TNBC

P. Schmid et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

The tumor microenvironment (TME) and atezolizumab plus nab-paclitaxel (A plus nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130.

Leisha A. Emens et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)-Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).

Peter Schmid et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).

Evan J. Lipson et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer

Hope S. Rugo et al.

Summary: This study evaluated different PD-L1 assays for triple-negative breast cancer patients and found that SP263 and 22C3 assays identified more PD-L1+ patients compared to SP142. A+nP treatment showed improved efficacy in patients with SP263+ and 22C3+ tumors compared to placebo+nP, with better outcomes in double-positive cases than single-positive cases. The concordance between different assays for PD-L1 detection was not perfect, and SP142 showed consistent efficacy in the IC >= 1% subgroup within 22C3 and SP263 PD-L1+ populations.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

添加到收藏夹

Article Medicine, General & Internal

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian et al.

Summary: Nivolumab plus chemotherapy showed superior overall survival and progression-free survival compared to chemotherapy alone in previously untreated patients with advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma, indicating it as a new standard first-line treatment option with acceptable safety profile.

LANCET (2021)

添加到收藏夹

Article Multidisciplinary Sciences

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

Thomas Powles et al.

Summary: The study found that using ctDNA testing to identify high-risk patients for relapse after surgery may improve treatment outcomes, with atezolizumab showing potential benefits in this patient population.

NATURE (2021)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

N. Colombo et al.

Summary: Adding pembrolizumab to chemotherapy significantly improves progression-free and overall survival in patients with persistent, recurrent, or metastatic cervical cancer when compared to placebo. Anemia and neutropenia are the most common grade 3 to 5 adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

D. F. Bajorin et al.

Summary: In a trial involving patients with high-risk muscle-invasive urothelial carcinoma who had undergone radical surgery, adjuvant nivolumab showed longer disease-free survival compared to placebo, especially among patients with a PD-L1 expression level of 1% or more, despite an increase in treatment-related adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy

Guangchun Han et al.

Summary: This study found that the loss of 9p21.3 leads to a cold tumor immune phenotype, reducing the responsiveness of tumors to immune checkpoint therapy and resulting in worse outcomes. By incorporating 9p21 loss, PD-L1 expression, and TMB levels in pre-treatment tumors, a response score was derived that can accurately identify patients likely to achieve sustained response to therapy.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Review Oncology

Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges

Shu-Jin Li et al.

Summary: Cancer immunotherapy has had significant success in recent years, but still faces challenges such as limited patient response. Combining immunotherapy with other therapies or antiangiogenic agents may help overcome resistance to monotherapy. Understanding the interactions between antiangiogenic agents and immunotherapy is crucial for improving treatment outcomes in solid tumors.

CANCER COMMUNICATIONS (2021)

添加到收藏夹

Article Oncology

Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study

Romualdo Barroso-Sousa et al.

Summary: This single-arm phase II study evaluating the combination of cabozantinib and nivolumab in metastatic triple-negative breast cancer did not show significant efficacy, and was stopped early due to toxicity. High levels of tumor immunosuppression were observed, as indicated by immunostaining, genomic, and proteomic studies.

NPJ BREAST CANCER (2021)

添加到收藏夹

Article Oncology

How can artificial intelligence models assist PD-L1 expression scoring in breast cancer: results of multi-institutional ring studies

Xinran Wang et al.

Summary: The use of deep learning-based artificial intelligence-assisted model improved the concordance and accuracy of PD-L1 scoring in breast cancer, providing a standardized approach for clinical practice.

NPJ BREAST CANCER (2021)

添加到收藏夹

Article Oncology

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

Peter Schmid et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Prevalence and mutational determinants of high tumor mutation burden in breast cancer

R. Barroso-Sousa et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer

Romualdo Barroso-Sousa et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Article Oncology

FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1

Preeti Narayan et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Pembrolizumab for the treatment of colorectal cancer

Dahna Coupez et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2020)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial

Rita Nanda et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer

Ami N. Shah et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Oncology

Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).

Delvys Rodriguez-Abreu et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119.

Eric P. Winer et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Oncology

Immunotherapy for pancreatic cancer: A 2020 update

Dimitrios Schizas et al.

CANCER TREATMENT REVIEWS (2020)

添加到收藏夹

Meeting Abstract Oncology

Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial

L. A. Emens et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Meeting Abstract Oncology

Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first- line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)

D. W. Miles et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Oncology

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

F. Cardoso et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: fi nal results from a phase I/II, single-arm, basket trial

K. Kalinsky et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study

Susan M. Domchek et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors

Lorenzo Galluzzi et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A decade of immune-checkpoint inhibitors in cancer therapy

Caroline Robert

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Medicine, General & Internal

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

Elizabeth A. Mittendorf et al.

LANCET (2020)

添加到收藏夹

Article Oncology

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurelien Marabelle et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

Leisha A Emens et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Editorial Material Oncology

How current assay approval policies are leading to unintended imprecision medicine

Roberto Salgado et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

Thomas Powles et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial

Sara M. Tolaney et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe

Carin A. Uyl-de Groot et al.

CANCERS (2020)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortes et al.

LANCET (2020)

添加到收藏夹

Article Oncology

Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy

Robert M. Samstein et al.

NATURE CANCER (2020)

添加到收藏夹

Article Oncology

Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers

S. Trebeschi et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Oncology

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

Leigh Marcus et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Editorial Material Biotechnology & Applied Microbiology

Defining the immunogram of breast cancer: a focus on clinical trials

Paolo Tarantino et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2019)

添加到收藏夹

Article Medicine, Research & Experimental

Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers

Tina Gruosso et al.

JOURNAL OF CLINICAL INVESTIGATION (2019)

添加到收藏夹

Article Oncology

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial

Sherene Loi et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Oncology

The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy

Adrienne G. Waks et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Meeting Abstract Oncology

Nimbus: A phase II study of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative breast cancer.

Romualdo Barroso-Sousa et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

Leonie Voorwerk et al.

NATURE MEDICINE (2019)

添加到收藏夹

Review Oncology

Current Landscape of Immunotherapy in Breast Cancer: A Review

Sylvia Adams et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Review Oncology

The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?

A. Elkrief et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

Shaveta Vinayak et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Review Oncology

Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives

E. Krasniqi et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)

添加到收藏夹

Meeting Abstract Oncology

RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with metastatic triple-negative breast cancer: KEYNOTE-086

Sherene Loi et al.

CANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

Gut Microbiome and Breast Cancer in the Era of Cancer Immunotherapy

Romualdo Barroso-Sousa et al.

CURRENT BREAST CANCER REPORTS (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Bertrand Routy et al.

SCIENCE (2018)

添加到收藏夹

Review Oncology

Immunotherapy of Primary Brain Tumors: Facts and Hopes

Robin A. Buerki et al.

CLINICAL CANCER RESEARCH (2018)

添加到收藏夹

Article Oncology

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Hope S. Rugo et al.

CLINICAL CANCER RESEARCH (2018)

添加到收藏夹

Meeting Abstract Oncology

ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011+/- nivolumab (nivo) in patients (pts) with advanced cancers.

Timothy Anthony Yap et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Meeting Abstract Oncology

Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.

David S. Hong et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

Jennifer K. Litton et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Oncology

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

Spencer C. Wei et al.

CANCER DISCOVERY (2018)

添加到收藏夹

Article Oncology

57PDTumor mutational burden and prognosis across pan-cancers

H Ding et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

P. Schmid et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

Luc Y. Dirix et al.

BREAST CANCER RESEARCH AND TREATMENT (2018)

添加到收藏夹

Article Oncology

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

Hussein A. Tawbi et al.

LANCET ONCOLOGY (2017)

添加到收藏夹

Article Multidisciplinary Sciences

CDK4/6 inhibition triggers anti-tumour immunity

Shom Goel et al.

NATURE (2017)

添加到收藏夹

Article Medicine, General & Internal

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

Mark Robson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Oncology

A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer

David L. Rimm et al.

JAMA ONCOLOGY (2017)

添加到收藏夹

Review Oncology

Clinical validity and Utility of Tumor-infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions

Lironne Wein et al.

FRONTIERS IN ONCOLOGY (2017)

添加到收藏夹

Article Oncology

The genomic landscape of breast cancer and its interaction with host immunity

Stephen Luen et al.

BREAST (2016)

添加到收藏夹

Review Oncology

Prognostic and predictive value of tumor in early breast cancer

Carmen Criscitiello et al.

CANCER TREATMENT REVIEWS (2016)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

R. L. Ferris et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Editorial Material Multidisciplinary Sciences

The cancer immunogram

Christian U. Blank et al.

SCIENCE (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

Nicholas McGranahan et al.

SCIENCE (2016)

添加到收藏夹

Review Oncology

Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy

Rajarsi Mandal et al.

CANCER DISCOVERY (2016)

添加到收藏夹

Review Oncology

Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes A Systematic Review

Sasha E. Stanton et al.

JAMA ONCOLOGY (2016)

添加到收藏夹

Article Medicine, General & Internal

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

D. T. Le et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Editorial Material Oncology

The immunogenicity of breast cancer-molecular subtypes matter

C. Denkert

ANNALS OF ONCOLOGY (2014)

添加到收藏夹

Article Oncology

PD-L1 Expression in Triple-Negative Breast Cancer

Elizabeth A. Mittendorf et al.

CANCER IMMUNOLOGY RESEARCH (2014)

添加到收藏夹

Review Oncology

A History of Cancer Chemotherapy

Vincent T. DeVita et al.

CANCER RESEARCH (2008)

添加到收藏夹

Article Multidisciplinary Sciences

Targeted cancer therapy

C Sawyers

NATURE (2004)

添加到收藏夹

Article Multidisciplinary Sciences

Molecular portraits of human breast tumours

CM Perou et al.

NATURE (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.